In 2026, compliance will hinge on RBQM integration, a governance loop that links risk with audit-ready evidence.
When RBQM Pilots Stall
Partial RBQM implementation is a structural weakness that exposes sponsors to risk and regulatory scrutiny.
The Non-Negotiable Standard in Clinical Trials
In 2026, global regulators will require RBQM in every stage of clinical trials
How Much Change Is Enough to Be Compliant with ICH E6(R3)?
Learn how to make the right changes, not just more changes, to meet compliance confidently.
Proportionality of Risk in Clinical Trials
Discover how proportionality of risk prioritises what truly matters to protect patients and ensure data integrity.
The Biggest Change in Clinical Trials Starts with Sponsors
As sponsors adapt to ICH R3, we explore whether sites are getting the support they need to keep up.
Quality by Design Is the Industry’s Best Bet for Clinical Trials
QbD is the most effective way to protect participants and data in clinical trials, yet the industry still struggles to make it a priority.
Why You Need to Be Clued Up on GCP in ICH E6 R3
TRI’s GCP e-learning module turns ICH E6(R3) principles into practical, scenario-based training.
Risk-Based Approaches
Risk-based approaches are everyone’s top priority in clinical trials, but no one seems to have a clear playbook.
TRI at Scope Europe 2025
TRI CEO Duncan Hall will be at Scope Europe 2025, sharing how technology is meeting the evolving needs of RBQM.